208 related articles for article (PubMed ID: 17371963)
1. Infiltration of a mesothelioma by IFN-gamma-producing cells and tumor rejection after depletion of regulatory T cells.
Rudge G; Barrett SP; Scott B; van Driel IR
J Immunol; 2007 Apr; 178(7):4089-96. PubMed ID: 17371963
[TBL] [Abstract][Full Text] [Related]
2. CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine.
Comes A; Rosso O; Orengo AM; Di Carlo E; Sorrentino C; Meazza R; Piazza T; Valzasina B; Nanni P; Colombo MP; Ferrini S
J Immunol; 2006 Feb; 176(3):1750-8. PubMed ID: 16424205
[TBL] [Abstract][Full Text] [Related]
3. Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25- and CD4+CD25- T cells.
Hilchey SP; De A; Rimsza LM; Bankert RB; Bernstein SH
J Immunol; 2007 Apr; 178(7):4051-61. PubMed ID: 17371959
[TBL] [Abstract][Full Text] [Related]
4. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.
Casares N; Arribillaga L; Sarobe P; Dotor J; Lopez-Diaz de Cerio A; Melero I; Prieto J; Borrás-Cuesta F; Lasarte JJ
J Immunol; 2003 Dec; 171(11):5931-9. PubMed ID: 14634104
[TBL] [Abstract][Full Text] [Related]
5. Determination of a CD4
Jafarinia M; Mehdipour F; Hosseini SV; Ghahramani L; Hosseinzadeh M; Ghaderi A
Tumour Biol; 2016 Nov; 37(11):14659-14666. PubMed ID: 27619682
[TBL] [Abstract][Full Text] [Related]
6. Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites.
Chaput N; Darrasse-Jèze G; Bergot AS; Cordier C; Ngo-Abdalla S; Klatzmann D; Azogui O
J Immunol; 2007 Oct; 179(8):4969-78. PubMed ID: 17911581
[TBL] [Abstract][Full Text] [Related]
7. Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors.
Nair RE; Kilinc MO; Jones SA; Egilmez NK
J Immunol; 2006 Jun; 176(12):7325-34. PubMed ID: 16751376
[TBL] [Abstract][Full Text] [Related]
8. [Tumor infiltrating regulatory T cells in human breast cancer and associated draining lymph nodes: an in-situ analysis].
Wang HY; Shi QF; Sun Y; He JJ; Wang YL
Zhonghua Bing Li Xue Za Zhi; 2013 Feb; 42(2):95-100. PubMed ID: 23710915
[TBL] [Abstract][Full Text] [Related]
9. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.
Ko K; Yamazaki S; Nakamura K; Nishioka T; Hirota K; Yamaguchi T; Shimizu J; Nomura T; Chiba T; Sakaguchi S
J Exp Med; 2005 Oct; 202(7):885-91. PubMed ID: 16186187
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.
Liyanage UK; Moore TT; Joo HG; Tanaka Y; Herrmann V; Doherty G; Drebin JA; Strasberg SM; Eberlein TJ; Goedegebuure PS; Linehan DC
J Immunol; 2002 Sep; 169(5):2756-61. PubMed ID: 12193750
[TBL] [Abstract][Full Text] [Related]
11. Activated CD8+ T-effector/memory cells eliminate CD4+ CD25+ Foxp3+ T-suppressor cells from tumors via FasL mediated apoptosis.
Kilinc MO; Rowswell-Turner RB; Gu T; Virtuoso LP; Egilmez NK
J Immunol; 2009 Dec; 183(12):7656-60. PubMed ID: 19923444
[TBL] [Abstract][Full Text] [Related]
12. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes.
Tanaka H; Tanaka J; Kjaergaard J; Shu S
J Immunother; 2002; 25(3):207-17. PubMed ID: 12000862
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytes.
Brillard E; Pallandre JR; Chalmers D; Ryffel B; Radlovic A; Seilles E; Rohrlich PS; Pivot X; Tiberghien P; Saas P; Borg C
Exp Hematol; 2007 Mar; 35(3):416-25. PubMed ID: 17309822
[TBL] [Abstract][Full Text] [Related]
14. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice.
Viehl CT; Moore TT; Liyanage UK; Frey DM; Ehlers JP; Eberlein TJ; Goedegebuure PS; Linehan DC
Ann Surg Oncol; 2006 Sep; 13(9):1252-8. PubMed ID: 16952047
[TBL] [Abstract][Full Text] [Related]
15. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
[TBL] [Abstract][Full Text] [Related]
16. Accelerating the secondary immune response by inactivating CD4(+)CD25(+) T regulatory cells prior to BCG vaccination does not enhance protection against tuberculosis.
Quinn KM; Rich FJ; Goldsack LM; de Lisle GW; Buddle BM; Delahunt B; Kirman JR
Eur J Immunol; 2008 Mar; 38(3):695-705. PubMed ID: 18266274
[TBL] [Abstract][Full Text] [Related]
17. Antitumor impact of interferon-γ producing CD1d-restricted NKT cells in murine malignant mesothelioma.
Tagawa T; Wu L; Anraku M; Yun Z; Rey-McIntyre K; de Perrot M
J Immunother; 2013 Oct; 36(8):391-9. PubMed ID: 23994885
[TBL] [Abstract][Full Text] [Related]
18. Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity.
Onda M; Kobayashi K; Pastan I
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4575-4582. PubMed ID: 30760587
[TBL] [Abstract][Full Text] [Related]
19. Combination of SLC administration and Tregs depletion is an attractive strategy for targeting hepatocellular carcinoma.
Chen L; Zhou S; Qin J; Hu H; Ma H; Liu B; Wang X; Ma J; Ye S; Zhong C; Zhou G; Liang C
Mol Cancer; 2013 Dec; 12(1):153. PubMed ID: 24304581
[TBL] [Abstract][Full Text] [Related]
20. CD4(+)CD25(+) T regulatory cells inhibit CD8(+) IFN-gamma production during acute and chronic FIV infection utilizing a membrane TGF-beta-dependent mechanism.
Fogle JE; Mexas AM; Tompkins WA; Tompkins MB
AIDS Res Hum Retroviruses; 2010 Feb; 26(2):201-16. PubMed ID: 20156102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
